All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 11 November 20262 min read

Ortin Global (ORTINGLOBE) Q2 FY27 Losses Narrow on Cost Cuts, But Revenue Remains Negligible

The pharmaceutical trader cut its quarterly loss by 47% year-on-year, but its revenue base is just ₹0.03 crore, raising questions about its operational scale.

By Abhinav Swaroop, CFA, Chief Business Officer: Hexawealth · Created 11 November 2026

Ortin Global's Q2 FY27 loss narrowed significantly as expenses fell, yet revenue remains at a negligible ₹0.03 crore. The company's future hinges on a leadership overhaul and a potential open offer, not on its current trading business.

For Ortin Global, the story is less about quarterly performance and more about corporate survival. The September quarter saw a smaller loss, but the underlying business is barely generating any sales, leaving investors to watch a leadership transition and a potential change in control.

The numbers show a company shrinking its losses while its top line remains microscopic. Revenue tripled year-on-year to ₹0.03 crore, but that is up from an almost non-existent base. The net loss improved to ₹0.27 crore, a 47% reduction from the year-ago period.

Revenue & profit

Revenue (₹ Cr)

Net Profit (₹ Cr)

Revenue & profitQ2 FY26 (Sep 2025) 0.01, Q3 FY26 (Dec 2025) 0.01, Q4 FY26 (Mar 2026) 0.31, Q1 FY27 (Jun 2026) 0.02, Q2 FY27 (Sep 2026) 0.03. Q2 FY26 (Sep 2025) -0.50, Q3 FY26 (Dec 2025) -0.05, Q4 FY26 (Mar 2026) -0.01, Q1 FY27 (Jun 2026) -0.34, Q2 FY27 (Sep 2026) -0.27-2-1012Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 0.01
  • Revenue (₹ Cr), Q3 FY26 (Dec 2025): 0.01
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 0.31
  • Revenue (₹ Cr), Q1 FY27 (Jun 2026): 0.02
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 0.03
  • Net Profit (₹ Cr), Q2 FY26 (Sep 2025): -0.50
  • Net Profit (₹ Cr), Q3 FY26 (Dec 2025): -0.05
  • Net Profit (₹ Cr), Q4 FY26 (Mar 2026): -0.01
  • Net Profit (₹ Cr), Q1 FY27 (Jun 2026): -0.34
  • Net Profit (₹ Cr), Q2 FY27 (Sep 2026): -0.27

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 (Sep 2025) 0.01, Q3 FY26 (Dec 2025) 0.01, Q4 FY26 (Mar 2026) 0.31, Q1 FY27 (Jun 2026) 0.02, Q2 FY27 (Sep 2026) 0.0300.511.52Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 0.01
  • Revenue (₹ Cr), Q3 FY26 (Dec 2025): 0.01
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 0.31
  • Revenue (₹ Cr), Q1 FY27 (Jun 2026): 0.02
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 0.03

Net Profit (₹ Cr)

Net Profit (₹ Cr)Q2 FY26 (Sep 2025) -0.50, Q3 FY26 (Dec 2025) -0.05, Q4 FY26 (Mar 2026) -0.01, Q1 FY27 (Jun 2026) -0.34, Q2 FY27 (Sep 2026) -0.27-2-1012Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Net Profit (₹ Cr), Q2 FY26 (Sep 2025): -0.50
  • Net Profit (₹ Cr), Q3 FY26 (Dec 2025): -0.05
  • Net Profit (₹ Cr), Q4 FY26 (Mar 2026): -0.01
  • Net Profit (₹ Cr), Q1 FY27 (Jun 2026): -0.34
  • Net Profit (₹ Cr), Q2 FY27 (Sep 2026): -0.27
MetricCurrentQ2 FY27 (Sep 2026)PreviousQ1 FY27 (Jun 2026)
Revenue (₹ Cr)
0.03
0.02
Net Profit (₹ Cr)
-0.27
-0.34

Why the loss is shrinking

The improvement in the bottom line came entirely from cost control, not sales growth. A report from ScanX noted that total expenses fell 41% year-on-year, primarily due to a sharp drop in other expenditure. Employee costs, however, remained a fixed burden, rising slightly. The company's pharmaceutical trading and real estate operations are not driving meaningful income.

The real story is corporate action

With no operational turnaround in sight, the market's focus has shifted. In September, the company overhauled its leadership, appointing a new Managing Director. More significantly, an open offer for a 26% stake by Mr. Parveen Satija at ₹14.65 per share was recommended by independent directors, as reported by FlashFinance. This corporate action, not quarterly sales, is the current driver of investor attention.

Key Points

  • Ortin Global's Q2 FY27 net loss narrowed to ₹0.27 crore, a 47% improvement year-on-year, driven by a 41% cut in total expenses.
  • Revenue remains negligible at ₹0.03 crore, highlighting a lack of scale in its pharmaceutical trading and real estate businesses.
  • The investment case revolves around corporate action, including a recent leadership reshuffle and a pending open offer for a 26% stake.

Hexa Perspective

The quarter confirms Ortin Global is in a holding pattern. Cost cuts can only shrink losses so far when revenue is virtually zero. The company's manufacturing license was cancelled years ago, and its shift to trading has not gained traction. The path forward now depends on the outcome of the open offer and whether new leadership can articulate a viable business plan. Until then, it remains a corporate shell with a listed status, where balance-sheet management outweighs operational performance.

Live Chart

· ORTINGLOBE

(BSE)

ISIN: INE749B01020

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Ortin Global (ORTINGLOBE) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Ortin Global's Q2 FY27 results?
For the quarter ended September 2026, Ortin Global reported revenue of ₹0.03 crore and a net loss of ₹0.27 crore. The loss narrowed by 47% compared to the same quarter last year, primarily due to a significant reduction in total expenses.
Why did Ortin Global's Q2 FY27 loss narrow despite low revenue?
Ortin Global's Q2 FY27 net loss narrowed by 47% year-on-year because total expenses fell sharply. According to a ScanX report, a 41% drop in 'other expenditure' was the primary driver, even as employee costs remained stable and revenue stayed at a negligible level.
What is the status of Ortin Global's manufacturing operations?
Ortin Global's manufacturing license was cancelled by the Telangana drug control administration in July 2023. The company has since shifted its focus to trading pharmaceuticals and real estate, but this has not generated meaningful revenue, as seen in the Q2 FY27 sales of just ₹0.03 crore.
Is there an open offer for Ortin Global shares?
Yes. An open offer for a 26% stake in Ortin Global by Mr. Parveen Satija at ₹14.65 per share has been recommended by the company's independent directors, as reported by FlashFinance. This corporate action is a key focus for investors alongside the quarterly results.
What caused the leadership changes at Ortin Global in September 2026?
Ortin Global overhauled its leadership in September 2026, appointing a new Managing Director and a Whole-time Director. This restructuring, reported by FlashFinance, occurred amid persistent financial challenges and extremely low promoter shareholding, potentially steering future corporate strategy.
What is Ortin Global's debt level?
Ortin Global has reported outstanding borrowings of ₹1.05 crore, which falls well below the ₹1,000 crore threshold to be classified as a 'Large Corporate' under SEBI norms. This indicates limited debt on its balance sheet.
How did Ortin Global's stock price react to the Q2 FY27 results?
Specific reaction data for November 14 is not available in the research. However, the stock was trading around ₹13.98 in the days leading up to the announcement. The market's focus has been more on corporate actions like the open offer than on the quarterly operational numbers.
What are analysts saying about Ortin Global after Q2 FY27?
There is no specific analyst rating or price target cited in the research for Q2 FY27. A MarketsMojo report from November 2026 compared Ortin Global to peers, noting it is loss-making with a price-to-book ratio of 8.52, which is high relative to some competitors.
What is Ortin Global's shareholding pattern?
As of the latest disclosure, promoter holding in Ortin Global is around 1.2%, with public shareholders owning the vast majority. Foreign institutional investor (FII) holding is minimal, at less than 2%, indicating limited institutional interest.
Ortin Global Q2 FY27 revenue
Ortin Global's revenue for the second quarter of FY27 (ended September 2026) was ₹0.03 crore. This represents a 200% increase year-on-year, but from an extremely low base of ₹0.01 crore in Q2 FY26.
Ortin Global net loss Q2 FY27
Ortin Global reported a net loss of ₹0.27 crore for Q2 FY27 (September 2026 quarter). This marks a 46% improvement compared to the net loss of ₹0.50 crore in the same quarter of the previous financial year.
Why did Ortin Global expenses decline in Q2 FY27?
Ortin Global's total expenses declined by 41% year-on-year in Q2 FY27. A ScanX report attributed this primarily to a sharp drop in 'other expenditure,' which fell from ₹47.80 lakh to ₹23.60 lakh compared to the year-ago quarter.